Idiopathic normal-pressure hydrocephalus is a neurologic disorder characterized by impaired gait, balance, cognition, and ...

The planned implementation of Medicaid work requirements provides an opportunity to obtain longitudinal data to guide ...

Tobacco use kills more than 7 million people worldwide each year, including 1.3 million who die from the effects of exposure to secondhand smoke.1 As a major contributor to cancer, cardiovascular ...

Obstructive sleep apnea is one of the most common respiratory disorders worldwide. Persons with obstructive sleep apnea can have loud snoring that is detrimental to social relationships and have ...

Michael Welsh, Jesús González, and Paul Negulescu have won the 2025 Lasker–DeBakey Clinical Medical Research Award for their roles in developing treatments for cystic fibrosis.

Previous results from this phase 3 trial showed that progression-free survival among participants with previously untreated EGFR (epidermal growth factor receptor)–mutated advanced non–small-cell lung ...

In our first Case Study in Social Medicine, a man presents to the emergency department reporting auditory hallucinations and suicidal thoughts. His case hinges on interpretations of whether his ...

There is an urgent need for low- and middle-income countries to ensure equitable, affordable, and sustained access to tobacco-cessation medications at scale.

Enactment of the Mental Health Parity and Addiction Equity Act in 2008 improved insurance coverage for mental health and addiction treatment. Now, the Affordable Care Act could affect the financing ...

The medical school application process has spiraled out of control, placing a huge and counterproductive burden on young aspiring physicians. What can be done to scale things down while improving t ...

A 4-year-old girl presented with a 3-day history of fever and dry cough. A chest radiograph showed a large, rounded opacity in the left lower lobe with subtle air bronchograms.

To the Editor: In the SELECT trial, Lincoff and colleagues (Dec. 14 issue) 1 found that weekly subcutaneous semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, was superior to placebo in ...